Post-kala-azar dermal leishmaniasis and leprosy: case report and literature review

Carregando...
Imagem de Miniatura
Citações na Scopus
16
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
BIOMED CENTRAL LTD
Citação
BMC INFECTIOUS DISEASES, v.15, article ID 543, 8p, 2015
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Post-kala-azar dermal leishmaniasis (PKDL) is a dermal complication of visceral leishmaniasis (VL), which may occur after or during treatment. It has been frequently reported from India and the Sudan, but its occurrence in South America has been rarely reported. It may mimic leprosy and its differentiation may be difficult, since both diseases may show hypo-pigmented macular lesions as clinical presentation and neural involvement in histopathological investigations. The co-infection of leprosy and VL has been reported in countries where both diseases are endemic. The authors report a co-infection case of leprosy and VL, which evolved into PKDL and discuss the clinical and the pathological aspects in the patient and review the literature on this disease. Case presentation: We report an unusual case of a 53-year-old female patient from Alagoas, Brazil. She presented with leprosy and a necrotizing erythema nodosum, a type II leprosy reaction, about 3 month after finishing the treatment (MDT-MB) for leprosy. She was hospitalized and VL was diagnosed at that time and she was successfully treated with liposomal amphotericin B. After 6 months, she developed a few hypo-pigmented papules on her forehead. A granulomatous inflammatory infiltrate throughout the dermis was observed at histopathological examination of the skin biopsy. It consisted of epithelioid histiocytes, lymphocytes and plasma cells with the presence of amastigotes of Leishmania in macrophages (Leishman's bodies). The diagnosis of post-kala-azar dermal leishmaniasis was established because at this time there was no hepatosplenomegaly and the bone marrow did not show Leishmania parasites thus excluding VL. About 2 years after the treatment of PKDL with liposomal amphotericin B the patient is still without PKDL lesions. Conclusion: Post-kala-azar dermal leishmaniasis is a rare dermal complication of VL that mimics leprosy and should be considered particularly in countries where both diseases are endemic. A co-infection must be seriously considered, especially in patients who are non-responsive to treatment or develop persistent leprosy reactions as those encountered in the patient reported here.
Palavras-chave
Post-kala-azar dermal leishmaniasis, Visceral leishmaniasis, Leprosy, Leprosy reactions
Referências
  1. Adams ER, 2013, J TROP MED, V2013
  2. Beena KR, 2003, J CUTAN PATHOL, V30, P616, DOI 10.1034/j.1600-0560.2003.00125.x
  3. Singh A, 2013, INDIAN J DERMATOL VE, V79, P360, DOI 10.4103/0378-6323.110795
  4. Saha S, 2007, J IMMUNOL, V179, P5592
  5. ELHASSAN AM, 1993, LEPROSY REV, V64, P53
  6. BARRAL A, 1991, AM J TROP MED HYG, V44, P536
  7. CORBETT CEP, 1993, AM J TROP MED HYG, V49, P616
  8. BADARO R, 1986, J INFECT DIS, V154, P1003
  9. Musa AM, 2002, ANN TROP MED PARASIT, V96, P765, DOI 10.1179/000349802125002211
  10. Ganguly S, 2010, INT J DERMATOL, V49, P921, DOI 10.1111/j.1365-4632.2010.04558.x
  11. Ramesh V, 2008, INT J DERMATOL, V47, P414, DOI 10.1111/j.1365-4632.2008.03621.x
  12. Kevric I, 2015, DERMATOL CLIN, V33, P579, DOI 10.1016/j.det.2015.03.018
  13. Salam MA, 2013, J HEALTH POPUL NUTR, V31, P294
  14. Salotra P, 2006, INDIAN J MED RES, V123, P295
  15. Mondal D, 2011, CURR OPIN INFECT DIS, V24, P418, DOI 10.1097/QCO.0b013e32834a8ba1
  16. Gasim S, 2000, ACTA TROP, V75, P35, DOI 10.1016/S0001-706X(99)00089-3
  17. Mukhopadhyay D, 2014, TRENDS PARASITOL, V30, P65, DOI 10.1016/j.pt.2013.12.004
  18. Tuon FF, 2014, AM J TROP MED HYG, V91, P81, DOI 10.4269/ajtmh.13-0578
  19. GRIMALDI G, 1993, CLIN MICROBIOL REV, V6, P230
  20. ELHASSAN AM, 1992, INT J DERMATOL, V31, P400, DOI 10.1111/j.1365-4362.1992.tb02668.x
  21. Rijal A, 2009, INT J DERMATOL, V48, P740, DOI 10.1111/j.1365-4632.2009.04018.x
  22. Shrivastava SB, 2004, INT J DERMATOL, V43, P428, DOI 10.1111/j.1365-4632.2004.02205.x
  23. Gasim S, 1998, CLIN EXP IMMUNOL, V111, P64
  24. Zijlstra EE, 2000, BRIT J DERMATOL, V143, P136, DOI 10.1046/j.1365-2133.2000.03603.x
  25. Schonian G, 2003, DIAGN MICR INFEC DIS, V47, P349, DOI 10.1016/S0732-8893(03)00093-2
  26. Nicodemo AC, 2013, REV INST MED TROP SP, V55, P429, DOI 10.1590/S0036-46652013000600011
  27. Arora S, 2014, INT J DERMATOL, V53, P606, DOI 10.1111/ijd.12299
  28. Das VNR, 2009, AM J TROP MED HYG, V80, P336
  29. Assis TS, 2008, EPIDEMIOL SERV SAUDE, V17, P107
  30. Bansal S, 2007, BRIT J DERMATOL, V157, P799
  31. Bittencourt Achiléa, 2003, Braz J Infect Dis, V7, P229, DOI 10.1590/S1413-86702003000300009
  32. da Saude M., 2007, MANUAL VIGILANCIA LE
  33. Desjeux P, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-196
  34. Diogenes M. J. N., 1992, Medicina Cutanea Ibero-Latino-Americana, V20, P20
  35. El Hassan AM, 2013, CASE REP MED, V2013
  36. Pelissari DM, 2011, BRASIL EPIDEMIOL, V20, P107
  37. Ramesh V, 1999, Indian J Dermatol Venereol Leprol, V65, P196
  38. Rathi Sanjay K, 2005, Indian J Dermatol Venereol Leprol, V71, P250
  39. Sanchez-Albisua B, 2013, INT J DERMATOL, V52, P887
  40. Sigh S, 2011, INT J DERMATOL, V50, P1099
  41. Verma N, 2015, BIOMED RES INT
  42. WHO, 2010, 949 WHO
  43. Zijlstra E E, 2003, Lancet Infect Dis, V3, P87, DOI 10.1016/S1473-3099(03)00517-6
  44. Zijlstra EE, 2001, T ROY SOC TROP MED H, V95, pS59, DOI 10.1016/S0035-9203(01)90219-6